Skip to main content

Table 1 Association of GCDFP-15 expression with baseline clinico-pathological parameters

From: Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes

  Total (100%) GCDFP-15 negative GCDFP-15 positive p
Total 602 363 (60.3%) 239 (39.7%) -
HR (n = 576)     0.034a
Negative 175 116 (66.3%) 59 (33.7%)
Positive 401 228 (56.9%) 173 (43.1%)
HER2 (n = 576)     0.035a
Negative 478 299 (62.6%) 179 (37.4%)
Positive 116 60 (51.7%) 56 (48.3%)
Biological tumor types (n = 569)     0.001b
HR+/HER2- 328 189 (57.6%) 139 (42.4%)
HR+/HER+ 68 37 (54.4%) 31 (45.6%)
HR-/HER2+ 43 19 (44.2%) 24 (55.8%)
HR-/HER2- 130 96 (73.8%) 34 (26.2%)
AR (n = 545)     <0.0001a
Negative 238 180 (75.6%) 58 (24.4%)
Positive 307 149 (48.5%) 158 (51.5%)
Age (n = 602)     0.066a
< 50 years 273 176 (64.5%) 97 (35.5%)
> = 50 years 329 187 (56.8%) 142 (43.2%)
Histological type (n = 602)     0.090b
Ductal/others 554 340 (61.4%) 214 (38.6%)
Lobular 48 23 (47.9%) 25 (52.1%)
Grading (n = 601)     <0.0001a
G1-2 463 261 (56.4%) 202 (43.6%)
G3 138 102 (73.9%) 36 (26.1%)
cT (n = 591)     0.181a
cT1-2 395 230 (58.2%) 165 (41.8%)
cT3-4 196 126 (64.3%) 70 (35.7%)
cN (n = 583)     0.008a
cN0 261 141 (54.0%) 120 (46.0%)
cN+ 322 209 (64.9%) 113 (35.1%)
  1. aFisher’s exact test.
  2. bPearson’s chi square test.